News & Updates

Show Multimedia Only

ORP-101 for IBS with diarrhoea misses mark in phase II trial

08 Apr 2026

The novel partial μ receptor agonist and full κ receptor antagonist ORP-101 has failed to demonstrate superiority to placebo in the treatment of patients with irritable bowel syndrome (IBS) with diarrhoea (IBS-D) in a phase II randomized controlled trial.

ORP-101 for IBS with diarrhoea misses mark in phase II trial

08 Apr 2026

Tavapadon shows promise as adjunct therapy for Parkinson’s Disease in phase III trial

08 Apr 2026 by

Tavapadon, a novel, investigational, selective D1/D5 agonist with once-daily oral dosing, provides clinically meaningful and sustained benefit adjunctive to levodopa and has a favourable safety profile in patients with Parkinson’s disease (PD) experiencing off fluctuations, according to findings of the TEMPO-3 trial.

Tavapadon shows promise as adjunct therapy for Parkinson’s Disease in phase III trial

08 Apr 2026

GLP-1 RAs may deter substance addiction, SUD-related adverse outcomes

07 Apr 2026 by

Initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) results in a lower risk of developing various incident substance use disorders (SUDs), suggests a study involving US veterans with type 2 diabetes (T2D). Its use also protects against adverse clinical outcome in people with pre-existing SUDs.

GLP-1 RAs may deter substance addiction, SUD-related adverse outcomes

07 Apr 2026

Patient tone influences AI-generated clinical advice in E-medicine

07 Apr 2026

A recent study has shown how large language models (LLMs) treat patient tone as clinical input, leading to adjustments in triage, follow-up, prescribing, and sick-leave decisions despite identical symptoms.

Patient tone influences AI-generated clinical advice in E-medicine

07 Apr 2026

Intravenous ferumoxytol bests oral ferrous sulfate for anaemia in pregnancy

07 Apr 2026

In the treatment of iron-deficiency anaemia in pregnancy, the use of intravenous (IV) ferumoxytol appears to lead to greater improvements in haemoglobin at delivery and more frequent resolution of anaemia compared with oral ferrous sulfate, according to an open-label randomized controlled trial.

Intravenous ferumoxytol bests oral ferrous sulfate for anaemia in pregnancy

07 Apr 2026

Mycophenolate mofetil as good as prednisone for preventing nephrotic syndrome relapse in kids

06 Apr 2026 by

In the treatment of children with idiopathic steroid-sensitive nephrotic syndrome, mycophenolate mofetil demonstrates noninferiority to prednisone in maintaining remission and reducing subsequent relapse, with the added benefit of reduced glucocorticoid-related toxic effects, according to the open-label phase III INTENT trial.

Mycophenolate mofetil as good as prednisone for preventing nephrotic syndrome relapse in kids

06 Apr 2026

ICONIC-ADVANCE 1-year data herald a shift in plaque psoriasis treatment

06 Apr 2026 by

Data from two phase III ICONIC-ADVANCE studies presented at AAD 2026 reinforce the potential of the investigational first-in-class targeted oral peptide icotrokinra for the treatment of plaque psoriasis (PsO).

ICONIC-ADVANCE 1-year data herald a shift in plaque psoriasis treatment

06 Apr 2026

GLP-1RA linked to reduced seizure recurrence risk in diabetic adults with epilepsy

06 Apr 2026

In adult patients with diabetes and epilepsy, treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) is associated with lower risks of seizure recurrence, hospitalization, and mortality compared with other glucose-lowering therapies, according to a retrospective study.

GLP-1RA linked to reduced seizure recurrence risk in diabetic adults with epilepsy

06 Apr 2026

Adagrasib shows promise in treatment of mutated solid tumours

05 Apr 2026

Treatment with the selective KRAS G12C inhibitor adagrasib significantly improves survival and yields high response rates in patients with KRAS G12C-mutant solid tumours, a study has shown.

Adagrasib shows promise in treatment of mutated solid tumours

05 Apr 2026

ASM use may be stopped right after resolution of acute provoked neonatal seizures

04 Apr 2026

In neonates with acute provoked seizures, continued use of antiseizure medications (ASMs) even after resolution of seizures may be unnecessary, as shown in a prospective, comparative effectiveness study.

ASM use may be stopped right after resolution of acute provoked neonatal seizures

04 Apr 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

ORP-101 for IBS with diarrhoea misses mark in phase II trial

ORP-101 for IBS with diarrhoea misses mark in phase II trial

Tavapadon shows promise as adjunct therapy for Parkinson’s Disease in phase III trial

Tavapadon shows promise as adjunct therapy for Parkinson’s Disease in phase III trial

GLP-1 RAs may deter substance addiction, SUD-related adverse outcomes

GLP-1 RAs may deter substance addiction, SUD-related adverse outcomes

Patient tone influences AI-generated clinical advice in E-medicine

Patient tone influences AI-generated clinical advice in E-medicine

Intravenous ferumoxytol bests oral ferrous sulfate for anaemia in pregnancy

Intravenous ferumoxytol bests oral ferrous sulfate for anaemia in pregnancy

Mycophenolate mofetil as good as prednisone for preventing nephrotic syndrome relapse in kids

Mycophenolate mofetil as good as prednisone for preventing nephrotic syndrome relapse in kids

ICONIC-ADVANCE 1-year data herald a shift in plaque psoriasis treatment

ICONIC-ADVANCE 1-year data herald a shift in plaque psoriasis treatment

GLP-1RA linked to reduced seizure recurrence risk in diabetic adults with epilepsy

GLP-1RA linked to reduced seizure recurrence risk in diabetic adults with epilepsy

Adagrasib shows promise in treatment of mutated solid tumours

Adagrasib shows promise in treatment of mutated solid tumours

ASM use may be stopped right after resolution of acute provoked neonatal seizures

ASM use may be stopped right after resolution of acute provoked neonatal seizures